BIOGEN INC. (BIIB) FY2024 Annual P&L / Income Statement

Income StatementCash FlowBalance Sheet

Revenue by Product and Service by Geography

2024-01-01 to 2024-12-31

Swipe to see the full flow
BIOGEN INC. (BIIB) FY2024 Annual P&L / Income StatementIncome statement for 2024-01-01 through 2024-12-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUE RECONCILIATIONREVENUEGROSSOPERATINGPRE-TAXNETProduct revenue, net - Rest of WorldProduct revenue, net - UNITED STATESSubtotal: Multiple Sclerosis - UNITED STATESSubtotal: Multiple Sclerosis - Rest of WorldSubtotal: Rare Disease - Rest of WorldSubtotal: Rare Disease - UNITED STATESSPINRAZA - Rest of WorldTYSABRI product - UNITED STATESTotal Fumarate - Rest of WorldTECFIDERA - Rest of WorldTYSABRI product - Rest of WorldSubtotal: Biosimilars - Rest of WorldTotal Fumarate - UNITED STATESSPINRAZA - UNITED STATESTotal Interferon - UNITED STATESVUMERITY - UNITED STATESBENEPALI - Rest of WorldAVONEX - UNITED STATESTotal Interferon - Rest of WorldCompleted technology for SKYCLARYS (U.S.) - UNITED STATESAVONEX - Rest of WorldIMRALDI - Rest of WorldTECFIDERA - UNITED STATESPLEGRIDY - Rest of WorldPLEGRIDY - UNITED STATESVUMERITY - Rest of WorldCompleted technology for SKYCLARYS (U.S.) - Rest of WorldZURZUVAE - UNITED STATESFAMPYRA - Rest of WorldFLIXABI - Rest of WorldSubtotal: Biosimilars - UNITED STATESBYOOVIZ - UNITED STATESQALSODY - UNITED STATESBYOOVIZ - Rest of WorldQALSODY - Rest of WorldFUMADERM And ADUHELM - Rest of WorldFUMADERM And ADUHELM - UNITED STATESTOFIDENCE - UNITED STATESOther - UNITED STATESOther - Rest of WorldRevenuesRevenue before reconciliation (calculated)Components above reported revenue (calculated)Gross profit (calculated)Cost of sales, excluding amortization and impairment of acquired intangible assetsOperating profit (calculated)Operating expenses (calculated)Selling, general and administrativeResearch and developmentAmortization and impairment of acquired intangible assetsCollaboration profit sharing/(loss reimbursement)Gain on sale of priority review voucher, netRestructuring charges(Gain) loss on fair value remeasurement of contingent considerationOther (income) expense, netIncome before income tax (benefit) expense and equity in (income) loss of investee, net of taxNet incomeIncome tax (benefit) expenseRevenue before reconciliation (calculated)Revenue beforereconciliation(calculated)$24.20 BGross profit (calculated)Gross profit(calculated)$7.37 BOperating profit (calculated)Operating profit(calculated)$1.91 BRevenuesRevenues$9.68 BIncome before income tax (benefit) expense and equity in (income) loss of investee, net of taxPretax income$1.91 BNet incomeNet income$1.63 BProduct revenue, net - Rest of WorldProduct revenue, net - Rest of World$3.98 BOperating expenses (calculated)Operating expenses(calculated)$5.46 BProduct revenue, net - UNITED STATESProduct revenue, net - UNITED STATES$3.24 BIncome tax (benefit) expenseIncome tax(benefit) expense$273.80 MSelling, general and administrativeSelling, general and administrative$2.40 BCost of sales, excluding amortization and impairment of acquired intangible assetsCost of sales$2.31 BSubtotal: Multiple Sclerosis - UNITED STATESSubtotal: MultipleSclerosis - UNITED STATES$2.19 BResearch and developmentResearch and development$2.04 BSubtotal: Multiple Sclerosis - Rest of WorldSubtotal: MultipleSclerosis - Rest of World$2.16 BAmortization and impairment of acquired intangible assetsAmortization and impairmentof acquired intangible assets$446.70 MSubtotal: Rare Disease - Rest of WorldSubtotal: Rare Disease- Rest of World$1.04 BCollaboration profit sharing/(loss reimbursement)Collaboration profitsharing/(loss reimbursement)$254.40 MGain on sale of priority review voucher, netGain on sale of priorityreview voucher, net−$88.60 MSubtotal: Rare Disease - UNITED STATESSubtotal: Rare Disease- UNITED STATES$947.70 MComponents above reported revenue (calculated)Components abovereported revenue(calculated)−$14.53 BSPINRAZA - Rest of WorldSPINRAZA - Rest of World$947.50 MRestructuring chargesRestructuring charges$30.20 MTYSABRI product - UNITED STATESTYSABRI - UNITED STATES$920.00 M(Gain) loss on fair value remeasurement of contingent consideration(Gain) loss on fairvalue remeasurement ofcontingent consideration$27.70 MTotal Fumarate - Rest of WorldTotal Fumarate - Rest of World$887.30 MTECFIDERA - Rest of WorldTECFIDERA - Rest of World$797.90 MOther (income) expense, netOther (income) expense, net$343.60 MTYSABRI product - Rest of WorldTYSABRI - Rest of World$795.00 MSubtotal: Biosimilars - Rest of WorldSubtotal: Biosimilars - Rest of World$769.00 MTotal Fumarate - UNITED STATESTotal Fumarate - UNITED STATES$707.80 MSPINRAZA - UNITED STATESSPINRAZA - UNITED STATES$625.70 MTotal Interferon - UNITED STATESTotal Interferon - UNITED STATES$562.70 MVUMERITY - UNITED STATESVUMERITY - UNITED STATES$538.60 MBENEPALI - Rest of WorldBENEPALI - Rest of World$479.10 MAVONEX - UNITED STATESAVONEX - UNITED STATES$451.30 MTotal Interferon - Rest of WorldTotal Interferon - Rest of World$405.30 MCompleted technology for SKYCLARYS (U.S.) - UNITED STATESCompleted technology forSKYCLARYS (U.S.) - UNITED STATES$301.10 MAVONEX - Rest of WorldAVONEX - Rest of World$256.20 MIMRALDI - Rest of WorldIMRALDI - Rest of World$213.10 MTECFIDERA - UNITED STATESTECFIDERA - UNITED STATES$169.20 MPLEGRIDY - Rest of WorldPLEGRIDY - Rest of World$149.10 MPLEGRIDY - UNITED STATESPLEGRIDY - UNITED STATES$111.40 MVUMERITY - Rest of WorldVUMERITY - Rest of World$89.40 MCompleted technology for SKYCLARYS (U.S.) - Rest of WorldCompleted technology forSKYCLARYS (U.S.) - Rest of World$81.40 MZURZUVAE - UNITED STATESZURZUVAE - UNITED STATES$72.20 MFAMPYRA - Rest of WorldFAMPYRA - Rest of World$71.70 MFLIXABI - Rest of WorldFLIXABI - Rest of World$63.20 MSubtotal: Biosimilars - UNITED STATESSubtotal: Biosimilars - UNITED STATES$24.10 MBYOOVIZ - UNITED STATESBYOOVIZ - UNITED STATES$23.00 MQALSODY - UNITED STATESQALSODY - UNITED STATES$20.90 MBYOOVIZ - Rest of WorldBYOOVIZ - Rest of World$13.60 MQALSODY - Rest of WorldQALSODY - Rest of World$11.50 MFUMADERM And ADUHELM - Rest of WorldFUMADERM AndADUHELM - Rest of World$7.50 MFUMADERM And ADUHELM - UNITED STATESFUMADERM And ADUHELM- UNITED STATES$2.80 MTOFIDENCE - UNITED STATESTOFIDENCE - UNITED STATES$1.10 MOther - UNITED STATESOther - UNITED STATES$75.00 MOther - Rest of WorldOther - Rest of World$7.50 M
Chart details

BIOGEN INC. (BIIB) FY2024 Annual P&L / Income Statement

Income statement for 2024-01-01 through 2024-12-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues
9,675,900,000 US dollars
Cost of sales, excluding amortization and impairment of acquired intangible assets
2,310,400,000 US dollars
Gross profit (calculated)
7,365,500,000 US dollars
Operating expenses (calculated)
5,459,500,000 US dollars
Operating profit (calculated)
1,906,000,000 US dollars
Other income (expense), net (calculated)
0 US dollars
Income before income tax (benefit) expense and equity in (income) loss of investee, net of tax
1,906,000,000 US dollars
Income tax (benefit) expense
273,800,000 US dollars
Net income
1,632,200,000 US dollars
AVONEX - UNITED STATES
451,300,000 US dollars
AVONEX - Rest of World
256,200,000 US dollars
BENEPALI - UNITED STATES
0 US dollars
BENEPALI - Rest of World
479,100,000 US dollars
BYOOVIZ - UNITED STATES
23,000,000 US dollars
BYOOVIZ - Rest of World
13,600,000 US dollars
Subtotal: Biosimilars - UNITED STATES
24,100,000 US dollars
Subtotal: Biosimilars - Rest of World
769,000,000 US dollars
FAMPYRA - UNITED STATES
0 US dollars
FAMPYRA - Rest of World
71,700,000 US dollars
FLIXABI - UNITED STATES
0 US dollars
FLIXABI - Rest of World
63,200,000 US dollars
FUMADERM And ADUHELM - UNITED STATES
2,800,000 US dollars
FUMADERM And ADUHELM - Rest of World
7,500,000 US dollars
Total Fumarate - UNITED STATES
707,800,000 US dollars
Total Fumarate - Rest of World
887,300,000 US dollars
IMRALDI - UNITED STATES
0 US dollars
IMRALDI - Rest of World
213,100,000 US dollars
Total Interferon - UNITED STATES
562,700,000 US dollars
Total Interferon - Rest of World
405,300,000 US dollars
Subtotal: Multiple Sclerosis - UNITED STATES
2,190,500,000 US dollars
Subtotal: Multiple Sclerosis - Rest of World
2,159,300,000 US dollars
Other - UNITED STATES
75,000,000 US dollars
Other - Rest of World
7,500,000 US dollars
PLEGRIDY - UNITED STATES
111,400,000 US dollars
PLEGRIDY - Rest of World
149,100,000 US dollars
QALSODY - UNITED STATES
20,900,000 US dollars
QALSODY - Rest of World
11,500,000 US dollars
Subtotal: Rare Disease - UNITED STATES
947,700,000 US dollars
Subtotal: Rare Disease - Rest of World
1,040,400,000 US dollars
Completed technology for SKYCLARYS (U.S.) - UNITED STATES
301,100,000 US dollars
Completed technology for SKYCLARYS (U.S.) - Rest of World
81,400,000 US dollars
SPINRAZA - UNITED STATES
625,700,000 US dollars
SPINRAZA - Rest of World
947,500,000 US dollars
TECFIDERA - UNITED STATES
169,200,000 US dollars
TECFIDERA - Rest of World
797,900,000 US dollars
TOFIDENCE - UNITED STATES
1,100,000 US dollars
TOFIDENCE - Rest of World
0 US dollars
TYSABRI product - UNITED STATES
920,000,000 US dollars
TYSABRI product - Rest of World
795,000,000 US dollars
VUMERITY - UNITED STATES
538,600,000 US dollars
VUMERITY - Rest of World
89,400,000 US dollars
ZURZUVAE - UNITED STATES
72,200,000 US dollars
ZURZUVAE - Rest of World
0 US dollars
Product revenue, net - UNITED STATES
3,237,300,000 US dollars
Product revenue, net - Rest of World
3,976,200,000 US dollars
Research and development
2,041,800,000 US dollars
Selling, general and administrative
2,403,700,000 US dollars
Amortization and impairment of acquired intangible assets
446,700,000 US dollars
Gain on sale of priority review voucher, net
negative 88,600,000 US dollars
Collaboration profit sharing/(loss reimbursement)
254,400,000 US dollars
Gain on sale of building, net
0 US dollars
Other (income) expense, net
343,600,000 US dollars
(Gain) loss on fair value remeasurement of contingent consideration
27,700,000 US dollars
Restructuring charges
30,200,000 US dollars
Revenue before reconciliation (calculated)
24,203,600,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
Components above reported revenue (calculated)
negative 14,527,700,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.
Equity in (income) loss of investee, net of tax
0 US dollars. Reported below-tax contribution to net income.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
  • Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
BIOGEN INC. (BIIB) FY2024 Annual P&L / Income Statement Sankey chart, Product and service — Product and Service by Geographical view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

76.1%

Gross profit / revenue

Operating margin

19.7%

Operating profit / revenue

Cash conversion

176.2%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!